Breast cancer risk in primary care: Implications for chemoprevention

Archives of Internal Medicine

Volumn 164, Issue 17, 2004, Pages 1897-1903

  Lewis, Carmen L ^a   Kinsinger, Linda S ^c   Harris, Russell P ^a,b   Schwartz, Robert J ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c VA Natl Ctr Hlth Prom Dis Prev   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; THROMBOEMBOLISM;

ADULT; AGED; ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; FEAR; FEMALE; HEALTH SURVEYS; HUMANS; HYSTERECTOMY; MIDDLE AGED; NORTH CAROLINA; PATIENT SELECTION; PRIMARY HEALTH CARE; RISK ASSESSMENT; TAMOXIFEN; THROMBOEMBOLISM;

EID: 4644248962     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.17.1897     Document Type: Article

References (19)

1. Kerlikowske K, Grady O, Rubin SM, Sandrock C, Ernster VL. Efficacy for screening mammography: a meta-analysis. JAMA. 1995;273:149-154.
2. Salzmann P, Kerlikowske K, Phillips K. Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age. Ann Intern Med. 1997;127:955-965.
3. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388.
4. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial: Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281:2189-2197.
5. Kinsinger LS, Harris R, Woolf SH, Sox HC, Lohr KN. Chemoprevention of breast cancer: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med. 2002;137:59-69.
6. US Preventive Services Task Force. Chemoprevention of breast cancer: recommendations and rationale. Ann Intern Med. 2002;137:56-58.
7. Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG, for the American Society of Clinical Oncology Working Group on Breast Cancer Risk Reduction Strategies: Tamoxifen and Raloxifene. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol. 1999;17:1939-1955.
8. Levine M, Moutquin J-M, Walton R, Feightner J. Chemoprevention of breast cancer: a joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. CMAJ. 2001;164: 1681-1690.
9. Gail MH, Costantino JH, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999;91: 1829-1846.
10. Gail MH, Brinton LA, Byar OP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879-1886.
11. National Cancer Institute Breast Cancer Risk Assessment Tool. Available at: http://bcra.nci.nih.gov/brc/. Accessed November 8, 2002. Personal digital assistant version available at: http://smi-web.stanford.edu/people/pcheng/ breastca/index .html. Accessed December 5, 2003.
12. Costantino JP, Gail MP, Pee O, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999;91: 1541-1548.
13. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001;93:358-366.
14. Kinsinger L, Harris R, Karnitschnig J. Worry about breast cancer in younger women: a major problem [abstract]. J Gen Intern Med. 1998;13(suppl):99.
15. Schnitt SJ, Connolly JL. Pathology of benign breast disorders. In: Harris JR, ed. Diseases of the Breast. 2nd ed. Philadelphia, Pa: Llppincott Williams & Wilkins; 2000:77.
16. Bastian LA, Lipkus IM, Kuchibhatla MN, et al. Women's interest in chemoprevention for breast cancer. Arch Intern Med. 2001;161:1639-1644.
17. Freedman AN, Graubard BI, Rao AR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemopreventlon. J Natl Cancer Inst. 2003;95:526-532.
18. Armstrong K, Eisen A, Weber B. Assessing the risk of breast cancer. N Engl J Med. 2000;342:564-571.
19. Cummings SR, Duong T, Kenyon E, Cauley JA, Whitehead M, Krueger KA. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA. 2002;287:216-220.